On December 10, 2025, China Pharma Holdings, Inc. (CPHI) disclosed a technology acquisition and related equity issuance. The 8-K filing disclosed a $6.3 million technology transfer agreement for a Captopril microcapsule patent and the issuance of 3.5 million restricted shares.

According to the filing, a subsidiary of China Pharma Holdings entered into a Technology Transfer Agreement on December 4, 2025, to acquire an invention patent for a Captopril microcapsule and its preparation method. The agreement specifies a total transfer price of $6.3 million, according to the SEC document.

The company will issue 3,500,000 restricted shares of common stock in connection with the technology transfer. The filing was signed by Zhilin Li, President and Chief Executive Officer of China Pharma Holdings, on behalf of the company.